FdaApplication
NDA 209939
Identifiers
- fda_app_no: NDA209939
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME CORP |
| application_type | NDA |
| approval_date | 2017-11-08 |
Revenue by product
PREVYMIS
| Period | Revenue |
|---|---|
| Q2 2026 | $295.0M |
| Q1 2026 | $272.0M |
| Q4 2025 | $276.0M |
| Q3 2025 | $266.0M |
| Q2 2025 | $228.0M |
| Q1 2025 | $208.0M |
| Q4 2024 | $215.0M |
| Q3 2024 | $208.0M |
| Q2 2024 | $188.0M |
| Q1 2024 | $174.0M |
| Q4 2023 | $175.0M |
| Q3 2023 | $157.0M |
| Q2 2023 | $143.0M |
| Q1 2023 | $129.0M |
| Q4 2022 | $118.0M |
| Q3 2022 | $114.0M |
| Q2 2022 | $103.0M |
| Q1 2022 | $94.0M |
| Q4 2021 | $100.0M |
| Q3 2021 | $96.0M |
| Q2 2021 | $93.0M |
| Q1 2021 | $82.0M |
| Q4 2020 | $81.0M |
| Q3 2020 | $77.0M |
| Q2 2020 | $63.0M |
| Q1 2020 | $60.0M |
| Q4 2019 | $50.0M |
| Q3 2019 | $45.0M |
| Q2 2019 | $38.0M |
| Q1 2019 | $32.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PREVYMIS | LETERMOVIR | 480MG | TABLET;ORAL |
| PREVYMIS | LETERMOVIR | 240MG | TABLET;ORAL |
2 products